Madhusmita Misra, MD, MPH; Sidhartha Pani, MD
DISCLOSURES January 27, 2026
GLP-1 receptor agonists (RAs) have transformed the management of type 2 diabetes and obesity by producing substantial weight loss and improving cardiometabolic risk profiles. Despite these benefits, concern remains regarding their effects on skeletal muscle, particularly the reduction in lean body mass observed during therapy.
Weight loss is typically accompanied by reductions in both fat and muscle mass. Although accumulating evidence suggests that GLP-1 RAs lead to modest decreases in absolute muscle mass, these changes are typically proportional to total weight loss, and may be accompanied by improvements in muscle quality and metabolic function.
Absolute Lean Mass vs Muscle Quality
“Absolute muscle mass” refers to total skeletal muscle tissue and is typically measured using MRI-based techniques, whereas lean body mass encompasses all nonfat components of the body, including muscle, bone, connective tissue, organs, and water. Across randomized trials and meta-analyses, reductions in lean body mass with GLP-1 RA therapy typically account for approximately 12%-40% of total weight loss, with many studies reporting values toward the lower end of this range. Reductions in absolute muscle mass appear to be smallest with liraglutide; larger decreases have been observed with semaglutide and tirzepatide. Importantly, these changes appear to be consistent with expected physiologic responses to weight loss and do not exceed age-related muscle decline when adjusted for the magnitude of weight reduction.
When lean mass is expressed as a percentage of body weight, GLP-1 RAs generally show no significant change in this measure , or even an increase from baseline. This suggests that muscle loss occurs proportionally alongside fat loss, or possibly to a lesser extent, rather than reflecting selective skeletal muscle loss. This distinction is clinically relevant because disproportionate muscle loss would increase the risk for sarcopenia, frailty, and functional decline, particularly among older adults and individuals with long-standing diabetes.
Muscle quality — defined by such factors as intramuscular fat content, mitochondrial efficiency, insulin sensitivity, and microvascular perfusion — has emerged as a more meaningful determinant of strength and physical function than muscle quantity alone. Multiple studies demonstrate that GLP-1 RAs preserve or improve muscle quality despite modest reductions in absolute muscle volume, primarily through reductions in myosteatosis and enhanced metabolic efficiency.
Adaptive Physiologic Responses
The most detailed human data come from MRI-based subanalyses of weight-loss studies, particularly the SURPASS-3 trial of tirzepatide. In this study, tirzepatide produced marked reductions in muscle fat infiltration across all doses, whereas reductions in muscle volume remained modest and proportional to overall weight loss. These compositional changes are consistent with adaptive physiologic responses to weight reduction rather than pathologic muscle wasting.
Several mechanisms appear to underlie these improvements in muscle quality. GLP-1 RAs increase microvascular blood flow within skeletal muscle, enhancing nutrient delivery and myocyte metabolism. They also improve insulin sensitivity and reduce muscle-derived inflammatory cytokines, leading to more favorable metabolic signaling. Preclinical studies further suggest direct muscle-protective effects, including anti-inflammatory and antioxidant actions, modulation of key signaling pathways (PI3K/Akt/mTOR and AMPK-PGC-1 alpha), suppression of proteolytic activity, and promotion of myogenic differentiation.
From a functional standpoint, available evidence remains limited, but data from preclinical studies and clinical trials suggest that muscle strength and physical performance are largely preserved during GLP-1 RA therapy. Meta-analyses evaluating grip strength, functional capacity, and cardiorespiratory fitness have not identified clinically meaningful impairments, supporting the hypothesis that improvements in muscle composition offset modest reductions in mass. This is particularly relevant for individuals with type 2 diabetes, in whom sarcopenia and impaired muscle function contribute to falls, fractures, and disability. However, additional clinical studies are needed to confirm these findings.
Beyond their established roles in obesity and diabetes management, the favorable effects of GLP-1 RAs on muscle metabolism have generated interest in their potential role in preventing or mitigating sarcopenia, especially in high-risk populations such as patients with chronic kidney disease. Although long-term outcome data are limited, current evidence suggests that GLP-1 RAs do not exacerbate muscle vulnerability in these patients.
Recommendations emphasize that regular resistance and weight-bearing exercise, combined with sufficient dietary protein intake, are essential to preserving muscle mass and strength during weight loss. When GLP-1 RA therapy is implemented within this framework, the risk for clinically significant muscle impairment seems to be minimal and the metabolic and cardiovascular benefits remain substantial.
Summary
GLP-1 RAs induce modest reductions in absolute muscle mass that are proportional to total weight loss while consistently improving muscle quality through reductions in intramuscular fat, enhanced insulin sensitivity, improved microvascular recruitment, and mitochondrial support. Together, these adaptations may be sufficient to preserve muscle strength and function in most patients, reframing lean mass loss as a physiologic and potentially adaptive response rather than a detrimental consequence of therapy.
